Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
POEMS syndrome is a paraneoplastic syndrome characterized by polyradiculoneuropathy (P), organomegaly (O), endocrinopathy (E), clonal plasma cell disorder (M), and skin changes (S). Other features include papilledema, extravascular volume overload, sclerotic bone lesions, thrombocytosis/erythrocytosis, and elevated VEGF levels.
Biomarker and diagnostic research for POEMS syndrome has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
8 clinical trials registered, 5 recruiting. Interventions under study include other interventions, drug therapy, and biologic therapy. Pipeline includes 2 PHASE2, 1 PHASE1, 1 EARLY_PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT05283993](https://clinicaltrials.gov/study/NCT05283993) |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 11:12 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about POEMS syndrome
A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH |
— |
Peking University First Hospital |
RECRUITING |
[NCT03717844](https://clinicaltrials.gov/study/NCT03717844) | Registry for Adults With Plasma Cell Disorders (PCD's) | — | UNC Lineberger Comprehensive Cancer Center | RECRUITING |
[NCT07448935](https://clinicaltrials.gov/study/NCT07448935) | One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS | — | Fondazione IRCCS Policlinico San Matteo di Pavia | RECRUITING |
[NCT06518876](https://clinicaltrials.gov/study/NCT06518876) | A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory POEMS Syndrome | PHASE1 | Novatim Immune Therapeutics (Zhejiang) Co., Ltd. | NOT_YET_RECRUITING |
[NCT07115654](https://clinicaltrials.gov/study/NCT07115654) | BCMA/CD3 BsAb Therapy for POEMS Syndrome | PHASE2 | Institute of Hematology & Blood Diseases Hospital, China | NOT_YET_RECRUITING |
145 publications have been identified in PubMed for POEMS syndrome. Research spans Case Report / Case Series (52%), Review / Meta-Analysis (20%), and Diagnostic / Biomarker (10%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 75 | 52% |
Research summaries | 29 | 20% |
Testing and diagnosis research | 15 | 10% |
Disease patterns and progression | 9 | 6% |
Clinical study results | 8 | 6% |
Laboratory research | 4 | 3% |
Other research | 3 | 2% |
New treatment approaches | 2 | 1% |
Di Y (2026). [PMID: 42077567](https://pubmed.ncbi.nlm.nih.gov/42077567/). *Int Med Case Rep J*. [Case Report / Case Series]
Tomkins O (2026). [PMID: 42161587](https://pubmed.ncbi.nlm.nih.gov/42161587/). *J Neurol Neurosurg Psychiatry*. [Case Report / Case Series]
Pugh CS (2026). [PMID: 42154614](https://pubmed.ncbi.nlm.nih.gov/42154614/). *J Adolesc Young Adult Oncol*. [Case Report / Case Series]
Bishara M (2026). [PMID: 41869173](https://pubmed.ncbi.nlm.nih.gov/41869173/). *Cureus*. [Case Report / Case Series]
He H (2026). [PMID: 41689769](https://pubmed.ncbi.nlm.nih.gov/41689769/). *Cancer*. [Epidemiology / Natural History]
Freiha J (2026). [PMID: 40813066](https://pubmed.ncbi.nlm.nih.gov/40813066/). *Practical neurology*. [Case Report / Case Series]
Hiroyasu S (2026). [PMID: 41243422](https://pubmed.ncbi.nlm.nih.gov/41243422/). *J Dermatol*. [Other]
Briani C (2026). [PMID: 41578669](https://pubmed.ncbi.nlm.nih.gov/41578669/). *Journal of the peripheral nervous system : JPNS*. [Diagnostic / Biomarker]
Fan M (2026). [PMID: 42147214](https://pubmed.ncbi.nlm.nih.gov/42147214/). *Front Oncol*. [Case Report / Case Series]
Armato V (2026). [PMID: 42122994](https://pubmed.ncbi.nlm.nih.gov/42122994/). *J Clin Med*. [Review / Meta-Analysis]
AI-curated news mentioning POEMS syndrome
Updated Sep 11, 2026
A recent case report highlights the co-presentation of pituitary abscess and POEMS-like syndrome, providing insights into the complex interplay between these conditions. This study may inform future research and clinical approaches to similar cases.
A recent study explores HIV-negative KSHV/HHV8-associated multicentric Castleman disease, highlighting its concurrent occurrence with Kaposi sarcoma and POEMS-like manifestations. This research adds to the understanding of complex interactions in rare diseases.
The academic CAR-T therapy ARI0002h demonstrates a minimal residual disease (MRD)-negative remission in patients with relapsed POEMS syndrome, showing a significant response correlated with sBCMA biomarker levels. This advancement could pave the way for new treatment strategies in this rare condition.
Tempest's TPST-2003 shows a 100% complete response rate in CAR-T-naïve patients with relapsed/refractory multiple myeloma (rrMM) and POEMS syndrome, indicating strong clinical potential. The dual-targeting CAR architecture may position TPST-2003 as a leading therapy if results are replicated in future trials.